Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bochum – page 96

1 704 clinical trials in Bochum, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bochum at a glance
1 704
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

1 704 trials in Bochum

Open in trial search

Study on Thoracic Radiotherapy and Durvalumab for Elderly or Frail Stage III Non-Small Cell Lung Cancer Patients Unable to Undergo Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study of luspatercept in patients with low-risk myelodysplastic syndrome (MDS) who do not require blood transfusions and have not received erythropoiesis treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:University of Leipzig

Study on Atezolizumab for Patients with High-Risk Stage II or Stage III Colorectal Cancer Not Eligible for Oxaliplatin Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AIO-Studien gGmbH

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Cholangiocarcinoma

Not recruiting

Study of Pemigatinib for Patients with Advanced Intrahepatic Cholangiocarcinoma with FGFR2 Changes After Local Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pemigatinib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study on the Effects of Risankizumab in Patients with Very Early Axial Spondyloarthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Risankizumab
  • Sponsor:St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Itolizumab
  • Sponsor:Equillium Inc.

Neuroblastoma+1

Not recruiting

Study of Palbociclib with Drug Combinations for Children and Young Adults with Recurrent or Refractory Neuroblastoma and Ewing Sarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Palbociclib
  • Sponsor:Pfizer Inc.

Hypercholesterolaemia

Not recruiting

Study on the Safety and Efficacy of MK-0616 for Adults with High Cholesterol

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enlicitide Chloride
  • Sponsor:Merck Sharp & Dohme LLC

Pulmonary fibrosis

Not recruiting

Study of Inhaled Pirfenidone for Patients with Progressive Pulmonary Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Avalyn Pharma Inc.

Study on Tafasitamab with Gemcitabine, Oxaliplatin, and Rituximab for Patients with Aggressive B-cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bochum

What the registry says about research in the country

01 Dermatology Research

Clinical trials focusing on skin conditions, including studies for cutaneous lupus erythematosus, hidradenitis suppurativa, and plaque psoriasis. Novel therapeutic approaches are being evaluated to improve treatment outcomes for patients with chronic skin disorders.

  • Cutaneous Lupus Treatment
  • Hidradenitis Suppurativa Management
  • Plaque Psoriasis Therapy

Multiple studies are investigating new medications for moderate to severe cases of these conditions.

02 Oncology Studies

Innovative research in cancer treatment, particularly focusing on colorectal cancer, pancreatic cancer, gastric cancer, and non-small cell lung cancer. These trials are evaluating targeted therapies and combination treatments.

  • Metastatic Colorectal Cancer
  • Pancreatic Ductal Adenocarcinoma
  • Advanced NSCLC

New therapeutic approaches combining immunotherapy with targeted treatments are being studied.

03 Cardiovascular and Metabolic Research

Studies focusing on heart failure prevention and chronic kidney disease management. Research includes innovative combination therapies and preventive approaches for high-risk patients.

  • Heart Failure Prevention
  • Chronic Kidney Disease
  • Post-COVID POTS

Trials are evaluating new treatment combinations to improve patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.